Results 51 to 60 of about 2,891 (162)
Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China Cohort
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Introduction
With an additional year of follow‐up compared with the previous report, this study presents the 27.2‐month efficacy and safety outcomes of the MajesTEC‐1 China cohort. Methods
A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE‐RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly ...Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du +20 morewiley +1 more sourceSelinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
Cells, 2020 Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific ...Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta +11 moredoaj +1 more sourceReal‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Background
The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. Aims
To evaluate treatment patterns and identify unmet clinical needs in RRMM across Italian hematology centers.Francesca Fazio, Alfonso Piciocchi, Paolo de Fabritiis, Messina Messina, Stefano Soddu, Valeria Sargentini, Francesco Di Raimondo, Francesca Patriarca, Pellegrino Musto, Maurizio Offidani, Elena Zamagni, Sara Bringhen, Massimo Gentile, Giuseppe Mele, Paola Fazi, MariaTeresa Petrucci, Michele Cavo +16 morewiley +1 more sourceProgerin Hinders Autophagy Flux at Its Final Stages in Hutchinson‐Gilford Progeria Syndrome Cells, Preventing Its Own Autophagic Degradation
Aging Cell, Volume 25, Issue 8, August 2026.We demonstrated that progerin induces the formation of autophagosomes but impairs their maturation and subsequent fusion with lysosomes. Progerin impedes proper autophagy flux, thus preventing its own autophagic degradation. Selinexor treatment improved both autophagosome maturation and autophagosome‐lysosome fusion, which ultimately led to effective ...Ian García‐Aguirre, Jesús Alejandro Reyes‐Martínez, Juan Unzueta, Francisco Guevara‐Namorado, Solangy Lizcano‐Meneses, Susana Gonzalo, Angel Baldan, Claudia Rangel, Gerardo J. Alanis‐Funes, Francisco Garcia‐Sierra, Kevin Ruiz‐Fajardo, Simon Gormes‐Pinchanski, Susana Castro‐Obregón, Aranza Meza‐Dorantes, Rocio Alejandra Chavez‐Santoscoy, Isabel Arrieta‐Cruz, Paola Tristán‐Aburto, Jonathan J. Magaña, Bulmaro Cisneros +18 morewiley +1 more sourceEnhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia
PharmaceuticalsBackground: Chronic myeloid leukemia is a hematological malignancy characterized by the abnormal proliferation of leukemic cells. Despite significant progress with tyrosine kinase inhibitors, such as Dasatinib, resistance remains a challenge.Mariarita Spampinato, Tatiana Zuppelli, Ilaria Dulcamare, Lucia Longhitano, Domenico Sambataro, Annalisa Santisi, Amer M. Alanazi, Ignazio A. Barbagallo, Nunzio Vicario, Rosalba Parenti, Alessandra Romano, Giuseppe Musumeci, Giovanni Li Volti, Giuseppe A. Palumbo, Francesco Di Raimondo, Anna Nicolosi, Sebastiano Giallongo, Vittorio Del Fabro +17 moredoaj +1 more sourceCombination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
npj Precision Oncology, 2022 Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the ...Nina Nguyen, Sana Chaudhry, Tulasigeri M. Totiger, Robert Diaz, Evan Roberts, Skye Montoya, Gabriel Pardo, Alejandro Pardo, Jumana Afaghani, Maurizio Affer, Jacob Jahn, Terrence Bradley, Francesco Maura, Dickran Kazandjian, Daniel Bilbao, Jennifer Chapman, Ola Landgren, James Hoffman, Justin Taylor +18 moredoaj +1 more sourceCesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement
British Journal of Haematology, Volume 209, Issue 2, Page 610-620, August 2026.ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea +25 morewiley +1 more sourceSurvival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology & Oncology, 2021 Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P. Vassilakopoulos, Priyanka Samal, Matthew Ku, Xiwen Ma, Kelly Corona, Kamal Chamoun, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Miguel Canales +33 moredoaj +1 more sourceSelinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series
eJHaemThis report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor.Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy +13 moredoaj +1 more sourceSystemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy
International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.What's new?
While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin +3 morewiley +1 more source
